Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Product type
Topic
- (-) Weight loss products (6)
- Advertising (234)
- COVID-19 (55)
- Compliance and enforcement (47)
- Vaping hub (33)
- Import and export (20)
- Medicinal cannabis hub (19)
- Safety monitoring and information (14)
- Scheduling (national classification system) (13)
- Manufacturing (10)
- Legislation (7)
- Labelling and packaging (4)
- Shortages and supply disruptions (4)
- Cosmetics (3)
- Prescription opioids hub (2)
- Unique Device Identification (UDI) hub (2)
- Committees and advisory bodies (1)
- Fees and payments (1)
- Sunscreens (1)
Type of content
Search
6 result(s) found, displaying 1 to 6
-
Media releasesThe TGA has updated its Advertising therapeutic goods on social media guidance to help advertisers to understand their responsibilities when promoting therapeutic goods via these platforms.
-
Media releasesWe have issued 10 infringement notices, totalling $198,000, to Midnight Health Pty Ltd (Midnight Health) for the alleged unlawful advertising of prescription-only weight-loss medicines.
-
Media releasesWe have accepted a court-enforceable undertaking from Your Solution Compounding Pharmacy Pty Ltd, regarding advertising of prescription-only compounded medicines for weight-loss.
-
Media releasesThe TGA reminds businesses and media outlets that it is unlawful to publicly advertise prescription-only medicines, including prescription-only weight loss medicines.
-
Media releasesAmendments to the Therapeutic Goods Regulations 1990 (Schedule 5, item 6) have been made resulting in compounded GLP-1 RA products no longer being able to be compounded by pharmacists and supplied to patients.
-
Media releasesThe TGA is aware of several scams targeting consumers seeking semaglutide (Ozempic). Consumers are strongly advised not to use products unless they have come from a trusted source.